Judson R. 2003. Using multiple drug exposure levels to optimize power in pharmacogenetic trials. J Clin Pharmacol, 43:816–24. Keck ME, Welt T, Muller MB, et al. 2003. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology, 28:235–43. Kendell RE. 2001. Five criteria for an improved taxonomy of mental disorders. Helzer JE, Hudziak JJ (eds). Defining psychopathology in the 21st Century. Washington: American Psychiatric Publ. p 3–18. Kendler KS, Neale MC, Kessler RC, et al. 1992. A population-based twin study of major depression in women. The impact of varying definitions of illness. Arch Gen Psychiatry, 49:257–66. Kennedy MB. 1998. Signal transduction molecules at the glutamatergic postsynaptic membrane. Brain Res Brain Res Rev, 26:243–57. Kim DK, Lim S-W, Lee S, et al. 2000. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport, 11:215–19. Klee CB, Ren H, Wang X. 1998. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem, 273:13367–70. Koch JM, Kell S, Hinze-Selch D, et al. 2002. Changes in CREB- phosphorylation during recovery from major depression. J Psychiatr Res, 36:369–75. Kohen R, Neumaier J, Hamblin M, et al. 2003. Congenitally learned helpless rats show abnormalities in intracellular signaling. Biol Psychiatry, 53:520–9. Kopnisky KL, Cowan WM, Hyman SE. 2002. Levels of analysis in psychiatric research. Dev Psychopathol, 14:437–61. Kunzel HE, Zobel AW, Nickel T, et al. 2003. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res, 37:525–33. Landgrebe J, Welzl G, Metz T, et al. 2002. Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J Psychiatr Res, 36:119–29. Laplante P, Diorio J, Meaney MJ. 2002. Serotonin regulates hippocampal glucocorticoid receptor expression via a 5-HT7 receptor. Brain Res Dev Brain Res, 139:199–203. Lemonde S, Turecki G, Bakish D, et al. 2003. Impaired repression at a 5- hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci, 23:8788–99. Leonard BE. 1996. New approaches to the treatment of depression. J Clin Psychiatry, 57:26–33. Lesch KP. 1998. Serotonin transporter and psychiatric disorders: listening to the gene. Neuroscientist, 4:25–34. Lesch KP, Hough CJ, Aulakh CS, et al. 1992. Fluoxetine modulates G protein alpha s, alpha q, alpha 12 subunit mRNA expression in rat brain. Eur J Pharmacol, 227:233–7. Levitan IB. 1994. Modulation of ion channels by protein phosphorylation and dephosphorylation. Annu Rev Physiol, 56:193–212. Li X, Witkin JM, Need AB, et al. 2003. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol, 23:419–30. Lotrich FE, Pollock BG. 2004. Meta-analysis of serotonin transporter polymorphisms and affective disorder. Psychiatr Genet. In press. Lotrich FE, Pollock BG, Ferrell RE. 2001. Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogenomics, 1:153–64. Lotrich FE, Pollock BG, Ferrell RE. 2003. Serotonin transporter promoter polymorphism in African Americans. Am J Pharmacogenomics, 3: 145–7. Lovlie R, Berle JO, Stordal E, et al. 2001. The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr Genet, 11:41–3. Lucek P, Hanke J, Reich J, et al. 1998. Multilocus nonparametric linkage analysis of complex trait loci with neural network. Hum Hered, 48:275–84. Neuropsychiatric Disease and Treatment 2005:1(1) Candidate genes for SSRI response Malberg JE, Eisch AJ, Nestler EJ, et al. 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci, 20:9104–10. Mancama D, Kerwin RW. 2003. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs, 17:143–51. Manji HK, Chen G. 2002. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry, 7:S46–56. Manji HK, Drevets WC, Charney DS. 2001. The cellular neurobiology of depression. Nat Med, 7:541–7. Mann CD, Vu TB, Hrdina PD. 1995. Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. Br J Pharmacol, 115:595–600. Marek GJ, Carpenter LL, McDougle CJ, et al. 2003. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology, 28:402–12. Mason DA, Moore JD, Green SA, et al. 1999. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1- adrenergic receptor. J Biol Chem, 274:12670–4. Massat I, Souery D, Del-Favero J, et al. 2002. Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders. Am J Med Genet, 114:177–85. McCarthy JJ, Hilfiker R. 2000. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol, 18:505–8. McLeod TM, Lopez-Figueroa AL, Lopez-Figueroa MO. 2001. Nitric oxide, stress, and depression. Psychopharmacol Bull, 35:24–41. Meira-Lima I, Jardim D, Junqueira R, et al. 2003. Allelic association study between phospholipase A2 genes and bipolar affective disorder. Bipolar Disord, 5:295–9. Messa C, Colombo C, Moresco RM, et al. 2003. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl), 167:72–8. Messina D, Annesi G, Serra P, et al. 2002. Association of the 5-HT6 receptor gene polymorphism C267T with Parkinson’s disease. Neurology, 58:828–9. Michaelovsky E, Frisch A, Rockah R, et al. 1999. A novel allele in the promoter region of the human serotonin transporter gene. Mol Psychiatry, 4:97–9. Millan MJ, Veiga S, Girardon S, et al. 2003. Blockade of serotonin 5- HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. Psychopharmacology (Berl), 168:397–409. Minov C, Baghai TC, Schule C, et al. 2001. Serotonin-2A-receptor and - transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett, 303:119–22. Miro X, Perez-Torres S, Artigas F, et al. 2002. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuro- pharmacology, 43:1148–57. Mitchell RJ, Howlett S, Earl L, et al. 2000. Distribution of the 3´ VNTR polymorphism in the human dopamine transporter gene in world populations. Hum Biol, 72:295–304. Miyamoto S, Asakura M, Sasuga Y, et al. 1997. Effects of long-term treatment with desipramine on microtubule proteins in rat cerebral cortex. Eur J Pharmacol, 333:279–87. Monaca C, Boutrel B, Hen R, et al. 2003. 5-HT1a/1b receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT1a and 5-HT1b knockout mice. Neuropsychopharmacology, 28:850–6. Moretti A, Gorini A, Villa RF. 2003. Affective disorders, antidepressant drugs and brain metabolism. Mol Psychiatry, 8:773–85. 31